Phaseline

Companies › Jiangsu Alphamab Biopharmaceuticals

Jiangsu Alphamab Biopharmaceuticals: clinical trials, targets and expected readouts

5 active drug programs in 9 registered trials: 7 Phase 1, 2 Phase 3; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
JSKN003
HER2-targeting antibody
–Phase 3Breast Cancer; Advanced Solid TumorDec 2026
JSKN016–Phase 3Triple Negative Breast Cancer; Advanced Malignant Solid Tumor; Inoperable Locally Advanced HER2-Negative Breast Cancer; Advanced Non-small Cell Lung CancerDec 2026
JSKN022–Phase 1Advanced Malignant Solid TumorsAug 2027
Furmonertinib Mesylate
EGFR tyrosine kinase inhibitor
EGFRPhase 1Advanced Non-small Cell Lung CancerJun 2028
JSKN021–Phase 1Advanced Malignant Solid TumorsOct 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05744427JSKN003Phase 1Advanced Solid TumorOncologyDec 2026
NCT06592417JSKN016Phase 1Advanced Malignant Solid TumorOncologyDec 2026
NCT06942234JSKN016Phase 1Inoperable Locally Advanced HER2-Negative Breast CancerOncologyJun 2027
NCT07292402JSKN022Phase 1Advanced Malignant Solid TumorsOncologyAug 2027
NCT06868732JSKN016Phase 1Advanced Non-small Cell Lung CancerOncologyJun 2028
NCT06868732Furmonertinib MesylatePhase 1Advanced Non-small Cell Lung CancerOncologyJun 2028
NCT07617727JSKN021Phase 1Advanced Malignant Solid TumorsOncologyOct 2028
NCT06079983JSKN003Phase 3Breast CancerOncologyMar 2029
NCT07533123JSKN016Phase 3Triple Negative Breast CancerOncologyMar 2029

Targets

EGFR (1)

Companies with the same targets

AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group

Companies built like this

Nanjing Sanhome Pharmaceutical ArriVent BioPharma Jiangsu Aosaikang Pharmaceutical HC Biopharma Wayshine Biopharm

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.